|
Nivolumab-IRDye800 Clinical Trials
2 actively recruiting trials across 1 location
▲ +1 trial since September 2026
Pipeline
Early 1: 2
Top Sponsors
- Vanderbilt-Ingram Cancer Center1
- Eben Rosenthal1
Indications
- Cancer2
- High Grade Glioma (HGG) of the Brain With BRAF Aberration1
- High Grade Gliomas1
- High Grade Glioma (III or IV)1
- HGG1
Nashville, Tennessee2 trials
Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)
Vanderbilt University Medical Center
Early 1
Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)
Vanderbilt University Medical Center
Early 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.